Skip to content

Intravenous Fluid for Pediatric Migraine in the Emergency Department

Single-blind, Placebo-challenge Study of Intravenous Fluid Hydration in the Management of Pediatric Migraine in the Emergency Department

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01073787
Acronym
EDMigraine3
Enrollment
46
Registered
2010-02-23
Start date
2010-07-01
Completion date
2012-11-01
Last updated
2026-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Headache, Migraine

Keywords

migraine, headache, pediatric, children, Emergency Department

Brief summary

The purpose of this study is to evaluate the effect of intravenous fluid (0.9% sodium chloride and water) alone on headache pain in children with migraine visiting the Emergency Department.

Detailed description

Migraine is a common and disabling disorder for children. The pain may be severe and relatively few effective medications are approved for use in children. The Emergency Department (ED) remains an important resource for children suffering from migraine whom have not responded to their usual therapy. While a number of effective intravenous therapies have been studied in adults, there has been only one such study in children. As such, emergency physicians have little or no information about the safety and efficacy of these medications in children. However, the conduct of clinical trials where pain is the outcome measure is often limited by a high placebo-response rate. The expectation of treatment can significantly alter the response to medications especially when pain severity is the outcome measure. Moreover, the investigators have found that intravenous fluid alone may help to treat migraine headache in children. The investigators propose a study to examine the response to intravenous fluid hydration as initial therapy comparing a group with expectation of medication and another group without the initial expectation of medication. The results of the study will help to estimate the rate of response to intravenous fluid and to evaluate the placebo-effect (i.e. expectation of treatment) in studies of migraine treatment in the ED. Exposure to additional and possibly unnecessary medications will thus be minimized and the results of future trials more definitive on the effect of the study medication.

Interventions

DRUGNormal saline

10 ml/kg of normal saline will be administered over 30 minutes

Sponsors

University of Alberta
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
5 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of migraine or probable migraine (with or without aura) per the International Classification of Headache Disorders (2nd edition) * Visiting the Emergency Department for migraine treatment * Emergency Department physician has chosen to administer intravenous medication * Has taken usual therapy at home or at least one does of either ibuprofen or acetaminophen in the Emergency Department

Exclusion criteria

* Other probable cause for headache (e.g. ventriculoperitoneal shunt, neoplasm, intracranial cyst) * Head trauma causing loss of consciousness within 1 week of presentation * Fever (temperature \> 38.5 oC) * Signs or symptoms of meningitis

Design outcomes

Primary

MeasureTime frameDescription
Headache pain30 minutesPain will be assessed using three measures: (1) Nine Faces Pain scale; (2) Visual Analogue Scale; and (3) Four categories (none, mild, moderate, or severe)

Secondary

MeasureTime frameDescription
Use of rescue medication24 hoursUse of any rescue medication after leaving the Emergency Department
Headache recurrence24 hoursRecurrence or worsening of headache after leaving the Emergency Department
Return to Emergency Department24 hoursReturn to Emergency Department for treatment of migraine within 24 hours
Vomiting30 minutes
Nausea30 minutesSeverity will be assessed using: (1) Visual Analogue Scale; (2) Four categories (none, mild, moderate, severe)

Countries

Canada

Contacts

PRINCIPAL_INVESTIGATORLawrence P Richer, MD, MSc

University of Alberta

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026